ET
VRTX icon

Entropy Technologies’s Vertex Pharmaceuticals VRTX Stock Holding History

Entropy Technologies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,693
Closed -$3.01M – 1183
2025
Q3 		$3.01M Buy
+7,693
New +$3.22M 0.23% 124
2024
Q3 		– Sell
-13,475
Closed -$6.32M – 941
2024
Q2 		$6.32M Buy
+13,475
New +$5.85M 0.68% 23
2024
Q1 		– Sell
-955
Closed -$389K – 881
2023
Q4 		$389K Buy
+955
New +$353K 0.07% 394

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Entropy Technologies's VRTX Position: Q4 2025 in Review

Entropy Technologies sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 7,693 shares — an estimated $3.01M sold.

Entropy Technologies first reported a position in VRTX in Q4 2023 and held it in 3 quarters. The position peaked at $6.32M in Q2 2024. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Entropy Technologies reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Entropy Technologies sold 7,693 Vertex Pharmaceuticals shares in Q4 2025, an estimated $3.01M.
  • Entropy Technologies first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Entropy Technologies's Vertex Pharmaceuticals position peaked at $6.32M in Q2 2024.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Entropy Technologies's 13F filing for Q4 2025, filed 13 Feb 2026.